Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions accepted — page 23

The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.

Submissions

681 documents · page 23 of 23

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-RECONSTITUTI/007Draft synthesis: Reconstitution practice and delivered doseDr Jacinta Grünbaum-SowandeAn indirect comparison is presented without an assessment of transitivity
DRAFT-RECONSTITUTI/002Draft synthesis: Reconstitution practice and delivered doseDr Mordecai Bellingham-OjoOverlapping primary studies across included reviews are counted more than once
DRAFT-PANCREATITIS/006Draft synthesis: Acute pancreatitis with incretin-based therapiesDr Fenella LavrentievAn indirect comparison is presented without an assessment of transitivity
DRAFT-PANCREATITIS/003Draft synthesis: Acute pancreatitis with incretin-based therapiesDr Wilhelmina WintringhamRisk-of-bias judgements are reported as an overall rating without the domains
DRAFT-PANCREATITIS/004Draft synthesis: Acute pancreatitis with incretin-based therapiesDr Matthias Whitmarsh-ObiQuantitative claims are reproduced without the method that produced them
DRAFT-ENDOTOXIN-IN/001Draft synthesis: Bacterial endotoxin in research-supply peptide…Dr Hamish Nyquist-ObioraIntention-to-treat and efficacy-estimand results are combined without distinction
DRAFT-ENDOTOXIN-IN/002Draft synthesis: Bacterial endotoxin in research-supply peptide…Dr Katarzyna Oppenheimer-AdeRisk-of-bias judgements are reported as an overall rating without the domains
DRAFT-PRIMARY-VS-S/006Draft synthesis: Cardiovascular benefit in primary compared with…Dr Ludmila TollemacheRisk-of-bias judgements are reported as an overall rating without the domains
DRAFT-PRIMARY-VS-S/007Draft synthesis: Cardiovascular benefit in primary compared with…Dr Liesbeth QuennevilleResults at materially different follow-up durations are pooled
DRAFT-PRIMARY-VS-S/005Draft synthesis: Cardiovascular benefit in primary compared with…Dr Jolyon Grünbaum-SowandeThe review does not say when it will be updated or what would trigger an update
DRAFT-PRIMARY-VS-S/001Draft synthesis: Cardiovascular benefit in primary compared with…Rosalind PetrossianStudies using different outcome definitions are pooled into one estimate
DRAFT-PRIMARY-VS-S/008Draft synthesis: Cardiovascular benefit in primary compared with…Dr Dmitri NordhagenAbsence of evidence is presented in a form a reader will take as negative evidence
DRAFT-PRIMARY-VS-S/009Draft synthesis: Cardiovascular benefit in primary compared with…Dr Zebedee Zaleski-MbekiQuantitative claims are reproduced without the method that produced them
DRAFT-PRIMARY-VS-S/002Draft synthesis: Cardiovascular benefit in primary compared with…Dr Rukayat Zaleski-MbekiA single-trial result is presented in the visual form of a pooled estimate
DRAFT-TIRZEPATIDE-/004Draft synthesis: Tirzepatide compared with semaglutide in type 2…Dr Oswin YorkstoneThe search strategy as published cannot be re-run
DRAFT-TIRZEPATIDE-/002Draft synthesis: Tirzepatide compared with semaglutide in type 2…Dr Delphine TrelawneyStudies using different outcome definitions are pooled into one estimate
DRAFT-PEPTIDE-PURI/004Draft synthesis: Dependence of reported purity on the analytical…Dr Ivo QuintanilhaAn indirect comparison is presented without an assessment of transitivity
DRAFT-MITOCHONDRIA/012Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Dr Mordecai Glendinning-UcheOverlapping primary studies across included reviews are counted more than once
DRAFT-MITOCHONDRIA/006Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Dr Fenella LavrentievThe review does not say when it will be updated or what would trigger an update
DRAFT-MITOCHONDRIA/008Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Dr Matthias Whitmarsh-ObiStudies using different outcome definitions are pooled into one estimate
DRAFT-MITOCHONDRIA/002Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Dr Kamila Glendinning-UcheThe same concept is given three different names in one document

page 23 of 23

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.